Taken together, our current results suggest that the proteasome catalytic subunits LMP2 and Y are closely linked to microglia-mediated inflammatory responses and that LMP2/Y inhibition may offer a new therapeutic strategy for neuroinflammatory diseases including AD. The gene discussed is PSMB9; the disease is Alzheimer disease.